Beyond Longevity: Why Women's Brain Health Deserves More Attention
by
Women account for almost two-thirds of people living with Alzheimer's disease. For years, the higher prevalence was largely attributed to the fact that women tend to live longer than men. But during a recent episode of The Progress Profile: Alzheimer's Research in Focus podcast, Phyllis Ferrell, DrPH, MBA, innovator, investor, and incubator for brain health and longevity, argued that explanation no longer tells the whole story.
In a conversation about the future of Alzheimer's research, moderator Dr. John Harrison, engaged Ferrell in conversation about the ways advances in biomarkers, cognitive testing, and precision medicine are revealing important biological differences between men and women. Their discussion highlighted an emerging area of research that could reshape everything from clinical trial design to early diagnosis and treatment.
“We're learning something that we've known in other disease states,” Ferrell said. “Women's brains are not just little men's brains.”
Looking beyond life expectancy
For decades, researchers have often associated women's higher rates of Alzheimer's disease with longevity. Since age remains the greatest risk factor for Alzheimer's, the assumption was that women were diagnosed more often because they lived longer. New technologies are allowing scientists to look deeper.
According to Ferrell, advances in biomarkers and more precise cognitive measurement are uncovering differences in how Alzheimer's develops and progresses in women. Rather than viewing sex as simply another demographic characteristic, researchers are beginning to recognize it as an important biological variable that may influence disease risk, progression, and response to treatment. It’s a shift that could have significant implications for both research and patient care.
One of the biggest obstacles, Ferrell noted, isn't that women are absent from Alzheimer's clinical trials. The larger problem is that researchers often fail to collect information that could explain important differences in cognitive aging.
“It's not so much the clinical trial participation,” Ferrell said. “We actually are pretty good in terms of the percentage of women that enroll in Alzheimer's clinical trials, but we haven't collected the data that we need.”
Most Alzheimer's studies enroll women after menopause, yet critical aspects of their reproductive history frequently go undocumented. Ferrell argued that researchers should be asking about the age of onset of menses, the age of onset of menopause, use of hormone replacement therapy, and other information that can provide more nuanced data.
Those details could prove essential for understanding how hormonal transitions influence brain aging. Without them, researchers may be overlooking patterns that affect cognitive decline, disease progression, and treatment response.
Menopause, hormones, and cognitive trajectories
The conversation also explored how hormonal transitions may influence cognitive health throughout a woman's life.
Although researchers have long studied menopause and hormone replacement therapy (HRT), many questions remain unanswered about how those experiences affect Alzheimer's risk and cognitive trajectories decades later.
Capturing reproductive milestones, including when menopause begins and whether HRT was used, could help scientists better understand why some women experience different patterns of cognitive decline than others. Those insights may ultimately support more personalized approaches to screening and treatment.
The discussion extended beyond biology to the tools researchers used to measure cognitive change.
Ferrell suggested that some commonly used cognitive assessments may unintentionally overlook meaningful sex differences because they were not designed with those differences in mind.
“We know boys' brains and girls' brains are different [and] the way we measure cognitive change could be different,” she said. “Some of the cognitive assessments that we use, maybe if they focus quite a bit…on visual spatial [skills], which from a gender bias perspective has a male leaning set of capabilities.”
Men tend to have advantages in visuospatial testing while women tend to perform better in tests of verbal abilities, Ferrell noted. If assessments emphasize one cognitive domain more than another, they may detect decline differently in men and women. Understanding those differences could improve researchers' ability to identify subtle cognitive changes earlier and more accurately.
Looking beyond life expectancy
For decades, researchers have often associated women's higher rates of Alzheimer's disease with longevity. Since age remains the greatest risk factor for Alzheimer's, the assumption was that women were diagnosed more often because they lived longer. New technologies are allowing scientists to look deeper.
According to Ferrell, advances in biomarkers and more precise cognitive measurement are uncovering differences in how Alzheimer's develops and progresses in women. Rather than viewing sex as simply another demographic characteristic, researchers are beginning to recognize it as an important biological variable that may influence disease risk, progression, and response to treatment. It’s a shift that could have significant implications for both research and patient care.
One of the biggest obstacles, Ferrell noted, isn't that women are absent from Alzheimer's clinical trials. The larger problem is that researchers often fail to collect information that could explain important differences in cognitive aging.
“It's not so much the clinical trial participation,” Ferrell said. “We actually are pretty good in terms of the percentage of women that enroll in Alzheimer's clinical trials, but we haven't collected the data that we need.”
Most Alzheimer's studies enroll women after menopause, yet critical aspects of their reproductive history frequently go undocumented. Ferrell argued that researchers should be asking about the age of onset of menses, the age of onset of menopause, use of hormone replacement therapy, and other information that can provide more nuanced data.
Those details could prove essential for understanding how hormonal transitions influence brain aging. Without them, researchers may be overlooking patterns that affect cognitive decline, disease progression, and treatment response.
Better data benefits everyone
Ferrell emphasized that studying women's brain health is not about prioritizing one group over another. Instead, it is about building a more complete understanding of the disease. Understanding how Alzheimer's develops in women may ultimately lead to better diagnosis, more personalized treatments, and improved outcomes across the entire population.
“It would show us how progression is different by gender. It would show us how the pathology is different by gender,” she said. “I would love to see us put more thought [into] that, not because I think it's more important to study women than men, but when you study women, you learn more about men, too.”
As Alzheimer's research enters an era of precision medicine, filling these data gaps may become just as important as developing new therapies. Understanding how sex differences, hormonal transitions, and reproductive history shape cognitive aging could help researchers identify risk earlier, tailor interventions more effectively, and ensure future discoveries benefit everyone.
To hear the full podcast and explore the ideas that are reshaping Alzheimer's research, listen to episode 2 of Progress Profile: Alzheimer's Research in Focus.